Robert L. Coleman, MD
Professor, Deputy Chair & Vice Chair, Clinical Research
The University of Texas MD Anderson Cancer Center
Unit 1362 P.O. Box 301439
Houston,
TX
USA
77230-1439
Biographical Sketch: Robert L. Coleman, MD is professor of gynecologic oncology and Vice-Chair, Clinical Research at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr Coleman received his doctor of medicine degree from Creighton University in Omaha, Nebraska and completed his obstetrics/gynecology residency at Northwestern University Medical Center in Chicago, Illinois; he completed his fellowship at The University of Texas MD Anderson Cancer Center. Dr Coleman’s research interests include novel therapeutics for ovarian, uterine, and cervical cancer, clinical trial development and statistical design, surgical innovations, and graduate education. He is MDACC’s Gynecologic Oncology Group (GOG) principal investigator (PI), serves on the GOG’s Ovarian and Developmental Therapeutics Committees, and is PI or co-PI for several GOG prospective clinical trials. He currently is a co-project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, the Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers. He is also funded by CPRIT to conduct a first-in-human trial of a systemically delivered siRNA product for gene silencing in solid tumors. Dr Coleman has authored or coauthored over 400 scientific publications, including over 180 peer-reviewed articles, numerous book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers, Prognostic and Predictive Factors in Gynecological Cancers, and Atlas of Gynecologic Oncology. Dr Coleman has served as a member of the Board of Directors for the Foundation for Women’s Cancer (formerly, the Gynecologic Cancer Foundation) and serves on the Council of the Society of Gynecologic Oncologists and on the Division of Gynecologic Oncology in ABOG. In June 2010 he was appointed to the Ann Rife Cox Chair in Gynecology."
Papers:
61 - Scientific Plenary
Molecular predictors of residual disease in patients with ovarian cancer
69 - Featured Poster
Launching personalized surgical therapy for advanced ovarian cancer
102 - Featured Poster
Not your mother's bisphosphonate: targeting angiogenesis in ovarian cancer
136 - Scientific Plenary
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 m
138 - Scientific Plenary
Health-related quality-of-life analysis from the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
171 - Poster Session A
A dose a day keeps the cancer away: metronomic albumin-bound paclitaxel and topotecan has potent antitumor activity in ovarian cancer
174 - Poster Session A
Is it equivalent?: a comparison of the clinical activity of Lipodox compared to Doxil in the treatment of recurrent ovarian cancer
236 - Poster Session A
Hitting the right mark: nonoverlapping Notch and PI3K alterations in ovarian cancer
284 - Poster Session A
Selective activation of Notch3 in high-grade serous ovarian cancer
326 - Poster Session A
Taking it up a Notch: implications for outcomes in endometrial cancer
354 - Poster Session B
Out with the old and in with the neoadjuvant: changes and influences in ovarian cancer practice patterns among Society of Gynecologic Oncology (SGO) members
439 - Poster Session B
Predicting everolimus/letrozole treatment efficacy in patients with advanced or recurrent endometrial cancer: a biomarker study
Questions & Panel Discussion
Faculty
Lecturette: Overview of Current Anti-Angiogenesis